NYSE:GSK - New York Stock Exchange, Inc. - US37733W2044 - ADR - Currency: USD
Taking everything into account, GSK scores 5 out of 10 in our fundamental rating. GSK was compared to 198 industry peers in the Pharmaceuticals industry. While GSK belongs to the best of the industry regarding profitability, there are concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on GSK.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 5.19% | ||
ROE | 22.27% | ||
ROIC | 17.01% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 24.96% | ||
PM (TTM) | 10% | ||
GM | 72.01% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.16 | ||
Debt/FCF | 4.76 | ||
Altman-Z | 1.83 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.87 | ||
Quick Ratio | 0.58 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 6.67 | ||
Fwd PE | 6.98 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 14.31 | ||
EV/EBITDA | 6.27 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 4.55% |
36.22
-0.13 (-0.36%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 4.55% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 6.67 | ||
Fwd PE | 6.98 | ||
P/S | 1.76 | ||
P/FCF | 14.31 | ||
P/OCF | 8.22 | ||
P/B | 3.92 | ||
P/tB | N/A | ||
EV/EBITDA | 6.27 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 5.19% | ||
ROE | 22.27% | ||
ROCE | 19.73% | ||
ROIC | 17.01% | ||
ROICexc | 19.17% | ||
ROICexgc | 55.58% | ||
OM | 24.96% | ||
PM (TTM) | 10% | ||
GM | 72.01% | ||
FCFM | 12.29% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 1.16 | ||
Debt/FCF | 4.76 | ||
Debt/EBITDA | 1.48 | ||
Cap/Depr | 88.68% | ||
Cap/Sales | 9.09% | ||
Interest Coverage | 12.49 | ||
Cash Conversion | 60.72% | ||
Profit Quality | 122.87% | ||
Current Ratio | 0.87 | ||
Quick Ratio | 0.58 | ||
Altman-Z | 1.83 |